Literature DB >> 23011471

Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis.

Qian Zhou1, Yu Mei, Takuhito Shoji, Xinbing Han, Karol Kaminski, Goo Taeg Oh, Pat P Ongusaha, Kunzhong Zhang, Hannah Schmitt, Martin Moser, Christoph Bode, James K Liao.   

Abstract

BACKGROUND: Macrophages play a central role in the development of atherosclerosis. However, the signaling pathways that regulate their function are not well understood. The Rho-associated coiled-coil-containing kinases (ROCK1 and ROCK2) are serine-threonine protein kinases that are involved in the regulation of the actin cytoskeleton. Recent studies suggest that ROCK1 in macrophages and bone marrow-derived cells mediates atherogenesis. However, a similar role for ROCK2 in the pathogenesis of atherosclerosis has not been determined. METHODS AND
RESULTS: The bone marrows from wild-type, ROCK2(+/-), and ROCK2(-/-) mice were transplanted into irradiated recipient low-density lipoprotein receptor(-/-) mice, and atherosclerosis was induced with a 16-week high-cholesterol diet. Compared with wild-type bone marrow-transplanted mice, ROCK2(+/-) bone marrow-transplanted and ROCK2(-/-) bone marrow-transplanted mice showed substantially less lipid accumulation in the aorta (8.46±1.42% and 9.80±2.34% versus 15.64±1.89%; P<0.01 for both) and decreased atherosclerotic lesions in the subaortic sinus (158.1±44.4 and 330.1±109.5×10(3)μm(2) versus 520.2±125.7×10(3)μm(2); P<0.01 for both). These findings correlated with decreased foam cell formation (2.27±0.57 versus 4.10±0.3; P<0.01) and increased cholesterol efflux (17.65±0.6 versus 9.75±0.8; P<0.05) in ROCK2-deficient mice that are mediated, in part, through the peroxisome proliferator-activated receptor-γ/liver X receptor/ATP-binding cassette transporter A1 pathway in macrophages.
CONCLUSIONS: ROCK2 contributes to atherosclerosis, in part, by inhibiting peroxisome proliferator-activated receptor-γ-mediated reverse cholesterol transport in macrophages, which contributes to foam cell formation. These findings suggest that inhibition of ROCK2 in macrophages may have therapeutic benefits in preventing the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011471      PMCID: PMC3807088          DOI: 10.1161/CIRCULATIONAHA.111.086041

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  Cell-substrate adhesion assays.

Authors:  M J Humphries
Journal:  Curr Protoc Cell Biol       Date:  2001-05

2.  A method for measuring Rho kinase activity in tissues and cells.

Authors:  Ping-Yen Liu; James K Liao
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

3.  Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo.

Authors:  K Miyata; H Shimokawa; T Kandabashi; T Higo; K Morishige; Y Eto; K Egashira; K Kaibuchi; A Takeshita
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

Review 4.  Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.

Authors:  Qian Zhou; Christoph Gensch; James K Liao
Journal:  Trends Pharmacol Sci       Date:  2011-01-16       Impact factor: 14.819

5.  Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages.

Authors:  Xinbing Han; Shiro Kitamoto; Qingyu Lian; William A Boisvert
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

6.  Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages.

Authors:  Hiroaki Okazaki; Masaki Igarashi; Makiko Nishi; Motohiro Sekiya; Makiko Tajima; Satoru Takase; Mikio Takanashi; Keisuke Ohta; Yoshiaki Tamura; Sachiko Okazaki; Naoya Yahagi; Ken Ohashi; Michiyo Amemiya-Kudo; Yoshimi Nakagawa; Ryozo Nagai; Takashi Kadowaki; Jun-ichi Osuga; Shun Ishibashi
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

7.  ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury.

Authors:  Kensuke Noma; Yoshiyuki Rikitake; Naotsugu Oyama; Guijun Yan; Pilar Alcaide; Ping-Yen Liu; Hongwei Wang; Daniela Ahl; Naoki Sawada; Ryuji Okamoto; Yukio Hiroi; Koichi Shimizu; Francis W Luscinskas; Jianxin Sun; James K Liao
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 8.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

Authors:  Alan R Tall; Laurent Yvan-Charvet; Naoki Terasaka; Tamara Pagler; Nan Wang
Journal:  Cell Metab       Date:  2008-05       Impact factor: 27.287

9.  Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice.

Authors:  Hong-Wei Wang; Ping-Yen Liu; Naotsugu Oyama; Yoshiyuki Rikitake; Shiro Kitamoto; Jonathan Gitlin; James K Liao; William A Boisvert
Journal:  FASEB J       Date:  2008-06-12       Impact factor: 5.191

10.  Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis.

Authors:  Motohiro Sekiya; Jun-Ichi Osuga; Shuichi Nagashima; Taichi Ohshiro; Masaki Igarashi; Hiroaki Okazaki; Manabu Takahashi; Fumiko Tazoe; Taeko Wada; Keisuke Ohta; Mikio Takanashi; Masayoshi Kumagai; Makiko Nishi; Satoru Takase; Naoya Yahagi; Hiroaki Yagyu; Ken Ohashi; Ryozo Nagai; Takashi Kadowaki; Yusuke Furukawa; Shun Ishibashi
Journal:  Cell Metab       Date:  2009-09       Impact factor: 27.287

View more
  19 in total

Review 1.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 2.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

3.  Attenuation of obesity-induced insulin resistance in mice with heterozygous deletion of ROCK2.

Authors:  H Soliman; J N Varela; V Nyamandi; M Garcia-Patino; G Lin; G R Bankar; Z Jia; K M MacLeod
Journal:  Int J Obes (Lond)       Date:  2016-05-10       Impact factor: 5.095

Review 4.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

5.  α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol.

Authors:  Rami Abu-Fanne; Emad Maraga; Ihab Abd-Elrahman; Aviel Hankin; Galia Blum; Suhair Abdeen; Nuha Hijazi; Douglas B Cines; Abd Al-Roof Higazi
Journal:  J Biol Chem       Date:  2015-10-30       Impact factor: 5.157

6.  Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase C674 promotes ischemia- and hypoxia-induced angiogenesis via coordinated endothelial cell and macrophage function.

Authors:  Yu Mei; Melissa D Thompson; Yasunaga Shiraishi; Richard A Cohen; Xiaoyong Tong
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

Review 7.  Rho/ROCK signaling in motility and metastasis of gastric cancer.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 8.  Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions.

Authors:  Linda Julian; Michael F Olson
Journal:  Small GTPases       Date:  2014-07-10

9.  Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages.

Authors:  Yanhua Fu; Yang Zhao; Bin Huang
Journal:  Exp Ther Med       Date:  2017-06-07       Impact factor: 2.447

10.  Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets.

Authors:  Nikola Sladojevic; Goo Taeg Oh; Hyung-Hwan Kim; Lea M Beaulieu; Hervé Falet; Karol Kaminski; Jane E Freedman; James K Liao
Journal:  Cardiovasc Res       Date:  2017-09-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.